PHAXIAM Therapeutics (BATS-CHIXE:PHXMP) - Aandelenkoers, Nieuws & Analyse

PHXMP Overzicht aandelen

A biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. Meer informatie

PHXMP fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( €17M )

Heeft geen zinvolle omzet ( €1M )

+ 1 meer risico

PHAXIAM Therapeutics S.A. Concurrenten

ProBiotix Health

OFEX:PBX

UK£10.7m

Verici Dx

AIM:VRCI

UK£8.2m

Genflow Biosciences

LSE:GENF

UK£6.1m

Oncimmune Holdings

AIM:ONC

UK£17.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor PHAXIAM Therapeutics
Historische aandelenkoersen
Huidige aandelenkoers	€2.21
52 Week Hoogtepunt	€0
52 Week Laag	€0
Bèta	1.86
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	-95.62%
Verandering sinds IPO	-97.85%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	PHXMP	GB Biotechs	GB Markt
7D	0%	1.5%	2.2%
1Y	n/a	-17.9%	8.8%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe PHXMP presteerde ten opzichte van de UK Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe PHXMP presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is PHXMP's price volatile compared to industry and market?
PHXMP volatility
PHXMP Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.6%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: PHXMP heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van PHXMP in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2004	68	Thibaut Fayet	www.phaxiam.com

PHAXIAM Therapeutics S.A. Samenvatting

Hoe verhouden de winst en inkomsten van PHAXIAM Therapeutics zich tot de beurswaarde?
PHXMP fundamentele statistieken
Marktkapitalisatie	€16.79m
Inkomsten(TTM)	-€23.49m
Inkomsten(TTM)	€1.33m

12.7x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is PHXMP overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
PHXMP resultatenrekening (TTM)
Inkomsten	€1.33m
Kosten van inkomsten	€0
Brutowinst	€1.33m
Overige uitgaven	€24.81m
Inkomsten	-€23.49m

Laatst gerapporteerde inkomsten

Dec 31, 2023

Volgende inkomensdatum

Sep 25, 2024

Winst per aandeel (EPS)	-2.35
Brutomarge	100.00%
Nettowinstmarge	-1,771.34%
Schuld/Eigen Vermogen Verhouding	39.8%

Hoe presteerde PHXMP op de lange termijn?

Bekijk historische prestaties en vergelijking

PHXMP Overzicht aandelen

Risicoanalyse

PHAXIAM Therapeutics S.A. Concurrenten

OFEX:PBX

UK£10.7m

AIM:VRCI

UK£8.2m

LSE:GENF

UK£6.1m

AIM:ONC

UK£17.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

Recent updates

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in U.S

PHAXIAM Therapeutics Announces the Validation of a New Investigator-Initiated Phase 2 Study

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

Insufficient new directors

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

No longer forecast to breakeven

No longer forecast to breakeven

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2023

Revenue misses expectations

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

PHAXIAM Therapeutics S.A. Samenvatting

12.7x

-0.7x

Inkomsten en omzet